Sinovac Biotech Co, Ltd
Biotech Co., Ltd. is a China-based biopharmaceutical company that aiming
to provide Chinese children with international quality vaccine and provide
Children in the world with vaccines made in China.
To achieve these objectives, Sinovac focuses research, development, manufacture and commercialization of vaccines for infectious diseases with significant unmet medical need.
Sinovac also provides services for diseases control and prevention, collaborating with the Chinese governments at the national, state and county levels.
Main products are Haelive（Hepatitis A vaccine），Inlive（Hand-Foot-Mouth Disease vaccine），Anful （Influenza vaccine）etc. The products have been sold to over 30 countries and regions in the world.
|Sales markets||Western Europe; Middle East; Asia; Africa; Central/South America|
|Affiliated categories:||Biomanufacturing |Sera and Vaccines More|
CPhI Worldwide 20195-7 November 2019 Frankfurt, Germany We were at stand 120D17 See our Exhibitor Profile See full Exhibitor List
CPhI South East Asia 201912-14 March 2019 Bangkok, Thailand We were at stand E2 See our Exhibitor Profile See full Exhibitor List
Our Top products
Inlive (Enterovirus Type 71 Vaccine , Inactivated )
Inlive is an original preventive vaccine in the world, independently developed by Sinovac Biotech Ltd., which is mainly used to prevent the Hand-Foot-Month Disease(HFMD) caused by Enterovirus Type 71(EV71) under 3 years old. The research of EV71 vaccine was initiated in May, 2008.Through close...
Healive (Hepatitis A Vaccine, Inactivated)
Healive is the first inactivated hepatitis A vaccine developed in China by Chinese scientists who retained the intellectual property rights. It brought to an end an era in which China did not have its own technology for developing and producing inactivated Hepatitis A vaccine. Healive received the new drug ce...More info
Anflu (Influenza Vaccine , Inactivated)
Sinovac commenced the development of its split influenza vaccine in 2001. The pre-clinical research was completed in 2004. The result of clinical trial for Anflu showed that it is well tolerated in children, adults and the elderly. In June 2006, Sinovac submitted the New Drug application to China State Food a...More info
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation